{"filing":{"accession_number":"0001104659-26-090094","cik":"0001875558","ticker":"NVCT","company_name":"Nuvectis Pharma, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"tm2622125d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926090094/tm2622125d1_8k.htm"},"events":[{"id":23825,"run_id":21550,"accession_number":"0001104659-26-090094","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Item 2.02 discloses Nuvectis's second quarter 2026 financial results via a press release furnished as Exhibit 99.1. The filing includes a complete Statement of Operations showing Q2 2026 net loss of $7.0 million versus $6.3 million in Q2 2025, balance sheet data as of June 30, 2026, and detailed operating expense breakdowns. This is a standard quarterly earnings release disclosure, material to investors assessing the company's financial condition and operational performance.","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24164,"accession_number":"0001104659-26-090094","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Nuvectis's second quarter 2026 financial results via a press release furnished as Exhibit 99.1. The filing includes a complete Statement of Operations showing Q2 2026 net loss of $7.0 million versus $6.3 million in Q2 2025, balance sheet data as of June 30, 2026, and detailed operating expense breakdowns. This is a standard quarterly earnings release disclosure, material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:20:21.512543+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24164,"accession_number":"0001104659-26-090094","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Nuvectis's second quarter 2026 financial results via a press release furnished as Exhibit 99.1. The filing includes a complete Statement of Operations showing Q2 2026 net loss of $7.0 million versus $6.3 million in Q2 2025, balance sheet data as of June 30, 2026, and detailed operating expense breakdowns. This is a standard quarterly earnings release disclosure, material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:20:21.512543+00:00","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-08-04"}]}